Bruker Co. (NASDAQ:BRKR) Shares Sold by Orion Portfolio Solutions LLC

Orion Portfolio Solutions LLC reduced its holdings in shares of Bruker Co. (NASDAQ:BRKR) by 26.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,258 shares of the medical research company’s stock after selling 14,570 shares during the period. Orion Portfolio Solutions LLC’s holdings in Bruker were worth $2,849,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of BRKR. First Horizon Advisors Inc. increased its holdings in shares of Bruker by 120.4% in the second quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 218 shares during the period. True Wealth Design LLC increased its holdings in shares of Bruker by 4,636.4% in the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 510 shares during the period. UMB Bank n.a. increased its holdings in shares of Bruker by 115.3% in the third quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 354 shares during the period. Gordian Capital Singapore Pte Ltd acquired a new position in shares of Bruker in the second quarter valued at about $52,000. Finally, GAMMA Investing LLC increased its holdings in shares of Bruker by 81.0% in the third quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock valued at $60,000 after purchasing an additional 388 shares during the period. 79.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BRKR has been the topic of a number of research reports. The Goldman Sachs Group raised Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price objective on the stock in a report on Thursday, December 5th. TD Cowen lowered their target price on Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research note on Wednesday, November 6th. Wolfe Research downgraded Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. Citigroup lowered their target price on Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Finally, UBS Group assumed coverage on Bruker in a research note on Tuesday. They issued a “neutral” rating and a $66.00 target price on the stock. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Bruker currently has a consensus rating of “Moderate Buy” and an average price target of $76.09.

Insider Activity

In other news, CEO Frank H. Laukien bought 100,000 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were acquired at an average price of $50.14 per share, for a total transaction of $5,014,000.00. Following the completion of the transaction, the chief executive officer now directly owns 38,439,563 shares in the company, valued at $1,927,359,688.82. The trade was a 0.26 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 28.30% of the company’s stock.

Bruker Stock Performance

Shares of BRKR stock opened at $59.98 on Wednesday. The company has a market capitalization of $9.09 billion, a P/E ratio of 28.84, a P/E/G ratio of 3.96 and a beta of 1.18. The business’s 50 day moving average is $59.32 and its two-hundred day moving average is $63.06. The company has a current ratio of 1.66, a quick ratio of 0.73 and a debt-to-equity ratio of 1.24. Bruker Co. has a 12-month low of $48.07 and a 12-month high of $94.86.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). The business had revenue of $864.40 million for the quarter, compared to analysts’ expectations of $866.46 million. Bruker had a return on equity of 21.52% and a net margin of 9.41%. The business’s revenue for the quarter was up 16.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.74 EPS. Analysts expect that Bruker Co. will post 2.4 EPS for the current fiscal year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Monday, December 2nd will be given a $0.05 dividend. The ex-dividend date of this dividend is Monday, December 2nd. This represents a $0.20 annualized dividend and a dividend yield of 0.33%. Bruker’s dividend payout ratio (DPR) is presently 9.62%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.